Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first-line setting.

R GenchevaM PetrovaP KralevaS HadjidekovaMaria Atanasova RadanovaN ConevD StoyanovJ ArabadjievE TazimovaS BachurskaM EnevaM TsvetkovaG ZhbantovT KaranikolovaD ManovA IvanovaM Taushanova-HadjievaR StanevaE DimitrovaIvan Shterev Donev

Published in: Cancer reports (Hoboken, N.J.) (2023)

We found that the prevalence of PIK3CA mutations in our patients was comparable to what has been reported in other nations. Our results suggest that PIK3CA mutational status has no bearing to ET efficacy in first-line setting.

Keyphrases

metastatic breast cancer
end stage renal disease
risk factors
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
stem cells